Full results from two Lilly trials of the novel triple hormone receptor agonist show reductions in A1c, osteoarthritis knee pain, and obstructive sleep apnea.

Patients with obesity and type 2 diabetes have more favorable QOL outcomes taking a GLP-1 than those with either condition alone or with multiple comorbidities.

Patients with RA have a higher risk of blood clots and serious infections with baricitinib vs older biologics, but not heart disease or cancer, according to two safety trials.

Cigarette smokers have a significantly lower likelihood of being diagnosed with Sjögren's disease, with histologic data showing less tissue damage and lower disease activity in smokers who have it.